Neurology · AnticonvulsantRegulatory Approvalregulatorymid-term

FDA Grants Approval for Gabapentin Supplement by Zhejiang Yongtai

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/3/2026, 6:31:53 AM

Assessment confidence: 64% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of a supplemental application for Gabapentin by Zhejiang Yongtai is significant as it strengthens their market position in a competitive landscape. Pharma strategy teams should evaluate the potential impact on pricing and market share dynamics among gabapentin manufacturers. Regulatory context from FDA (FDA AP — GABAPENTIN (SUPPL)) supports the near-term read. Assessment grounded in 20 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this approval on market share and pricing strategies for gabapentin products. The strongest clinical anchor is Korean Post-marketing Surveillance for Xeljanz XR (ClinicalTrials.gov), sponsor/company relevance (pfizer). In Neurology · Anticonvulsant, 6 regulatory and 3 competitive items passed relevance filtering for Gabapentin.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for NUPLAZID Supplement NDA210793 (Humanexa Signals) — moderate corpus alignment. Secondary pressure from FDA Grants Approval for Sugammadex Sodium (ANDA218814) by SteriScience. This approval may enhance Zhejiang Yongtai's position in the gabapentin market, potentially impacting competitors with similar products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — GABAPENTIN (SUPPL) (FDA). Entity match (gabapentin). The approval indicates a successful regulatory pathway for Zhejiang Yongtai, which may influence future submissions and compliance strategies for other companies in the sector.

Key Risks

Elevated medium regulatory exposure for Gabapentin could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Korean Post-marketing Surveillance for Xeljanz XR) could weigh on Gabapentin through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

This approval may lead to increased market share for Zhejiang Yongtai, potentially affecting revenue and competitive positioning of other gabapentin products.
Upside for Gabapentin may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Portfolio teams should assess the implications of this approval on market share and pricing strategies for gabapentin products.

What Would Change This Assessment

This becomes more urgent if Monitor market response and any subsequent competitive actions from other gabapentin manufacturers.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin)
FDA document
View source
FDA AP — GABAPENTIN (ORIG)
FDAhigh relevance
Entity match (gabapentin)
FDA document
View source
Advancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs - 08/27/2026
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source

Korean Post-marketing Surveillance for Xeljanz XR
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
E-cigarette Social Media Marketing and Its Perceptions by Youth
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Post-marketing Observational Study of Oral Cholera Vaccine
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for NUPLAZID Supplement NDA210793
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Sugammadex Sodium (ANDA218814) by SteriScience
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves JAKAFI XR (Ruxolitinib Phosphate) Submission by Incyte
Humanexa Signalsmedium relevance
Moderate corpus alignment

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Gabapentin
competitors in the gabapentin market

Commercial impact

medium

This approval may lead to increased market share for Zhejiang Yongtai, potentially affecting revenue and competitive positioning of other gabapentin products.

Regulatory impact

medium

The approval indicates a successful regulatory pathway for Zhejiang Yongtai, which may influence future submissions and compliance strategies for other companies in the sector.

What to watch

Monitor market response and any subsequent competitive actions from other gabapentin manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.